Xingmou Biotech Secures Tens of Millions in Series A2 Funding to Advance Dual-Target Gene Therapy for nAMD

Sep 19, 2025 16:37 CST Updated 16:37

StarryGene

Gene Therapy Drug Developer

▲November 6-7The 10th Guangzhou (Greater Bay Area) BiomedicalInnovators Summit Scan to register

Note:This article does not constitute any investment opinions or suggestions, please refer to the official information./Official company announcements shall prevail;This article only introduces drugs related to medical health, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprinted must obtain authorization.

PharmaCircleMonitoring shows:Recently, StarryGene, a biotechnology company from Hefei, Anhui, China, has completed an A2 round of financing worth tens of millions of RMB., this round of financing was jointly completed by Cowin Venture Capital, Guoke Venture Capital, and others.

The funds from this round of financing will provide important financial support for StarryGene's product development, with a focus on advancing the company’s core products—Phase II Clinical Trial of wAMD Product XMVA09, and simultaneously promotedAMDPipeline andTEDPipeline’s pharmaceutical, preclinical research, and IIT clinical trials.

StarryGene is a high-tech enterprise based on cutting-edge gene editing technology to develop ophthalmic disease gene therapy products, focusing on the development of ophthalmic gene therapy drugs. The core team of StarryGene is a doctoral entrepreneurial team led by a "Distinguished Young Scholar," possessing two core technology platforms on the R&D side: the AAV-Antibody Gene Drug Platform (Dual Antibody Optimization Platform, Capsid Screening Platform) and the Gene Editing Platform.

Previously, in June this year, the University of Science and Technology of China, the First Affiliated Hospital of USTC, and the StarryGene team published a breakthrough research achievement in the journal "Research," developing a specific targeting of retinal pigment epithelial cells (RPE).Adeno-Associated Virus (AAV) Vector XMVA09. This vector, administered via intravitreal injection, can express a bispecific antibody that simultaneously targets VEGF-A and angiopoietin-2 (ANG-2), effectively treating neovascular age-related macular degeneration (nAMD). Key highlights of the study include: 1. ThroughIn vivo directed evolution technologyDeveloped an AAV vector with RPE cell targeting that surpasses AAV2.7m8, efficiently infecting RPE cells; 2. A dual-target treatment strategy that achieves long-term effective bispecific antibody expression with a single administration.Avoid Frequent InjectionsAnimal model validation showed that XMVA09 significantly reduced fluorescein leakage and CNV lesions, improved retinal thickness, and demonstrated stronger therapeutic effects in laser-induced CNV mice and rhesus monkey models. This study provides a more convenient and efficient treatment option for nAMD patients.

Moxie Pharma Data pharma.bcpmdata.com (formerly known as PharmaCloud Data)

References:

Moxie Pharma Data pharma.bcpmdata.com (formerly PharmaCloud Data);

etc.。

Note: After remarking, you can scan the code to join the PharmaCircle communication group.

The following conferences are featured in the header image; you can scan the banner in the header image to register.

Rooted in Shanghai and radiating globally, PharmaCircle, as a biopharmaceutical industry-level strategic platform, is committed to the mission of "enabling the boundless flow of intelligence and connections." It builds a comprehensive industrial chain empowerment system covering drug R&D, production, distribution, and commercialization. Through four core engines—intelligent cloud services, precise resource linking, industry think tanks, and ecosystem communities—it establishes the infrastructure for the flow of pharmaceutical value in China.

Under the dual waves of globalization and digitalization, PharmaCircle is redefining the circulation paradigm of pharmaceutical resources — it is not only a hub for information and networking but also a catalyst for industrial transformation. With China as the origin, we are weaving a global network of pharmaceutical intelligence, making every precise connection a catalyst for enterprises' leapfrog growth.

Like

Share

Point Recommendation